Flutamide-induced hepatic dysfunction in relation to steady-state plasma concentrations of flutamide and its metabolites

Molecular and Cellular Biochemistry

Volumn 252, Issue 1-2, 2003, Pages 149-156

  Aizawa, Yoshio ^a,c   Ikemoto, Isao ^a   Kishimoto, Koichi ^a   Wada, Tetsuro ^a   Yamazaki, Haruki ^a   Ohishi, Yukihiko ^a   Kiyota, Hiroshi ^a   Furuta, Nozomu ^a   Suzuki, Hidenori ^b   Ueda, Masataka ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Fuji City General Hospital   (Japan)

^c Fuji City General Hospital ^*  (Japan)

Author keywords

Flutamide; Hepatic dysfunction; Hydroxyflutamide; Metabolic idiosyncrasy; Metabolites

Indexed keywords

ANTIANDROGEN; DRUG METABOLITE; FLUTAMIDE; GONADORELIN AGONIST; HYDROXYFLUTAMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; FREQUENCY ANALYSIS; HUMAN; HYPOTHESIS; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PROSPECTIVE STUDY; PROSTATE CANCER; STEADY STATE; TIME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; FLUTAMIDE; HUMANS; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 12444310801     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025560513308     Document Type: Article

References (21)

1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989
2. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, Labrie F: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 92: 465-470, 1992
3. Cetin M, Demirci D, Unal A, Altinbas M, Guven M, Uluhizarci K: Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. Hum Exp Toxicol 18: 137-140, 1991
4. Cortes MG, Andrade RJ, Lucena MI, Martinez HS, Fermandez MC, Ferrer T, Martin-Vivaldi R, Pelaez G, Suarez F, Rosemary-Gomez M, Montero JL, Fraga E, Camargo R, Alcantara R, Pizarro MA, Garcia-Ruiz E: Rev Esp Enferm Dig 93: 428-432, 2001
5. Yamaguchi A, Ozono S, Kitauchi T, Nakanou I, Torimoto K, Fujimoto K, Hirao Y: Study of flutamide-induced liver disorders. Nishinihon J Urol 63: 469-471, 2001
6. Nakagawa Y, Koyama M, Matsumoto M: Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer. Acta Urol Jpn 45: 821-826, 1999
7. Wada T, Ueda M, Abe K, Kobari T, Yamazaki H, Nakata J, Ikemoto I, Ohishi Y, Aizawa Y: Risk factor of liver disorders caused by flutamide - statistical analysis using multivariate logistic regression analysis. Acta Urol Jpn 45: 521-526, 1999
8. Zimmerman HJ: Drug-induced liver disease. In: E.R. Schiff, M.F. Sorrell, W.C. Maddley (eds). Diseases of the Liver. Lippincott-Raven, Philadelphia, 1999, pp 973-1064
9. Kachen B, Buxbaum S: Disposition of a new, nonsteroid, antiandrogen, α-α-αtrifluoro-2-methyl-4′-nitro-m-propionotoluidide (Flutamide), in men following a single oral 200 mg dose. J Clin Endocrinol Metab 41: 373-379, 1975
10. Schulz M, Schmoldt A, Donn F, Becker H: The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Clin Pharmacol 34: 633-636, 1988
11. Radwanski E, Perentesis G, Symchowicz S, Zampaglione N: Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. J Clin Pharmacol 29: 554-558, 1989
12. Asakawa N, Koyama M, Hashimoto Y, Yamashita K: Studies on the metabolic fate of flutamide (I): Plasma concentration after single administration and protein binding in rats. Xenobio Metabol Dispos 10: 447-453, 1995
13. Asakawa N, Koyama M, Hashimoto Y, Yamashita K: Studies on the metabolic fate of flutamide (4): Biliary excretion, enterohepatic circulation, absorption from gastro-intestinal tract, metabolism and drug-metabolizing enzymes induction in rats. Xenobio Metabol Dispos 10: 470-483, 1995
14. Jewett HJ: The present status of radical prostatectomy for stage A and B prostate cancer. Urol Clin North Am 2: 105-124, 1975
15. Siest G, Schieie F, Galteau MM, Panek E, Steinmetz J, Fagnani F, Gueguen R: Aspartate aminotransferase and alanine aminotransferase activities in plasma: Statistical distributions, individual variations, and reference values. Clin Chem 21: 1077-1087, 1975
16. Kuntz E, Kuntz H-D: Hepatology: Principles and Practice. Springer-Verlag, Berlin, 2001. pp 77-84
17. Shet MS, Mcphaul M, Ficher CW, Stallings NR, Estabrook RW: Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab Dispos 25: 1298-1303, 1997
18. Anjum S, Swan SK, Lambrecht LJ, Radwanski E, Cutler DL, Affrime MB, Halstenson CE: Pharmacokinetics of flutamide in patients with renal insufficiency. Br J Pharmacol 47: 43-47, 1999
19. Fan D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, Pessayre D: Toxicity of antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 269: 954-962, 1994
20. Wysowski DK, Fourcroy JL: Flutamide hepatotoxicity. J Urol 155: 209-212, 1996
21. Kojima M, Kamoi K, Ukimura O, Fujito A, Nakao M, Tanaka S, Miyashita H, Iwamoto N, Ohe H, Kitamori T, Date S, Kitamura K, Araki H, Aoki T, Imada N, Takada H, Imaide Y, Mikami K, Uchida M, Saitoh M, Miki T: Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: A preliminary study. Int J Urol 9: 42-46, 2002